



Araştırma Yazısı

2021; 30: 113-117

INVESTIGATION OF ENZYME INHIBITORY PROPERTIES AND ANTIOXIDANT ACTIVITY OF *CAPPARIS OVATA* DESF. VAR. *PALAESTINA* ZOH. FLOWER AND FRUIT EXTRACTS
CAPPARIS OVATA DESF. VAR. *PALAESTINA* ZOH. BİTKİSİNİN ÇİÇEK VE MEYVE EKSTRELERİNİN ENZİM İNHİBİTÖR ÖZELLİKLERİ VE ANTİOKSİDAN ETKİLERİNİN ARAŞTIRILMASI

Leyla PAŞAYEVA¹, Ayşe Kübra KARABOĞA ARSLAN²¹Erciyes University, Faculty of Pharmacy, Department of Pharmacognosy, Kayseri²Erciyes University, Faculty of Pharmacy, Department of Pharmacology, Kayseri**ABSTRACT**

In this study, the inhibiting effect on α -amylase and α -glucosidase and the antioxidant activity of ethanol extracts from flower and fruit of *Capparis ovata* var. *palaestina* was investigated. The antioxidant activity of the extracts was tested with DPPH•, ABTS•+ and FRAP methods. According to the results, the highest α -glucosidase and α -amylase activity were found in fruit extract ($IC_{50}=271.72\pm 0.41$ and 142.07 ± 0.85 μ g/mL, respectively). Also, the highest TPC (26.40 ± 0.02 mgGAE/gextract) and TFC (8.33 ± 0.30 mgCA /gextract) were found in the same extract and this extract showed the highest DPPH• activity (32%). Although, flower extract showed the highest FRAP values (at a concentration of 1 mg/mL equivalent to 262.69 ± 2.27 mmol Fe²⁺) and ABTS•+ (at a concentration of 0.5 mg/mL equivalent to 0.18 ± 0.01 μ M Trolox) activity. In conclusion, it is thought that these studies will shed light on future studies on this species.

Keywords: Capparaceae, diabetes, DPPH, α -amylase, α -glucosidase.

ÖZ

Bu çalışmada *Capparis ovata* var. *palaestina* bitkisinin çiçek ve meyvelerinden hazırlanan etanol ekstresinin α -amilaz ve α -glikozidaz inhibitör etkisi ve antioksidan özelliği araştırılmıştır. Ekstrelerin antioksidan etkisi DPPH•, ABTS•+ve FRAP testleri kullanılarak değerlendirilmiştir. Sonuçlara göre en yüksek α -amilaz ve α -glikozidaz etki meyve ekstresinde bulunmuştur (sırasıyla, $IC_{50}=271.72\pm 0.41$ ve 142.07 ± 0.845 μ g/ml). Ayrıca en yüksek TPC (26.40 ± 0.02 mgGAE/g_{extract}) ve TFC (8.33 ± 0.30 mgCA /g_{extract}) değerleri ve DPPH• (% 32) etkisi de aynı ekstrede görülmüştür. Bununla birlikte çiçek ekstresi en yüksek FRAP değerleri (1 mg/ml konsantrasyonda 262.69 ± 2.27 mmol Fe²⁺ eşdeğer) ve ABTS•+ (0.5 mg/ml konsantrasyonda 0.18 ± 0.01 μ M Troloks'a eşdeğer) aktivite göstermiştir. Sonuç olarak, yapılan çalışmanın bu bitki üzerinde ileride yapılacak çalışmalara ışık tutacağı düşünülmektedir.

Anahtar kelimeler: Capparaceae, diyabet, DPPH, α -amilaz, α -glikozidaz.

Makale Geliş Tarihi : 15.04.2021

Makale Kabul Tarihi: 07.07.2021

Corresponding Author: Dr. Öğr. Üyesi Leyla PAŞAYEVA,
Department of Pharmacognosy, Faculty of Pharmacy, Erciyes
University, Kayseri 38030, Turkey.
ORCID ID:0000-0003-3860-7222
E-mail: leylapasayeva@erciyes.edu.tr
Telefon: +90-352-207-6666 / 28277
Ayşe Kübra KARABOĞA ARSLAN, aysekubra@erciyes.edu.tr,
ORCID: 0000-0002-4689-0657

INTRODUCTION

Diabetes mellitus (DM) is a group of complex and chronic metabolic disorders with diverse multiple etiologies. It is characterized by high blood glucose (hyperglycemia) resulting from malfunction in insulin secretion and/or insulin action, both leading to impair metabolism of carbohydrates, lipids and proteins. The alterations in the utilization of complex biomolecules by the most affected tissues (liver, muscle and adipose tissue) due to hyperglycemia initiate a sequence of oxidative processes that cause dysfunction and failure of other organs in the body. Long-term complications may affect the organs such as kidneys, eyes, nerves, heart and blood vessels, and in absence of effective treatment result into death (1,2).

At present, different approaches are used to control diabetes using modern synthetic anti-diabetic drugs, insulin injection and life style modification. The synthetic anti-diabetic drugs include sulphonylureas, glucosidase inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and biguanide. However, these synthetic drugs have characteristic profiles of serious side effects, which include hypoglycemia, weight gain, gastrointestinal discomfort and nausea, liver and heart failure, and diarrhoea (3,4).

These limitations coupled with an exponential increase in the prevalence of diabetes motivate researchers to scientifically validate the folkloric use of a number of medicinal plants and/or their isolated bioactive compounds as possible alternative therapies for diabetes.

Capparis L. is one of the widespread genus of the Capparaceae family. The Caper (*Capparis*) is known as kapari, keper, kebere, and gevil in different regions of Turkey (5). There are two species in Turkey (*C. spinosa* L. and *C. Ovate* Desf.) and each species is represented by three varieties as *C. spinosa* L. var. *spinosa* L., *C. spinosa* L. var. *inermis* Turra., *C. spinosa* L. var. *aegyptia* (Lam) Boiss, *C. ovata* Desf. var. *palaestina* Zoh., *C. Ovate* Desf. var. *herbacea* (Wild) Zoh. and *C. ovate* Desf. var. *canescens* (Coss.) Heywood (6). Caper which is an economically valuable plant is being used for food, drug and cosmetic purposes (5). Additionally, there are various studies on *C. ovata* as antidiabetic (6), antioxidant (6,5), hepatoprotective(7), anticancer (8), wound healing (9), anti-neuro inflammatory (10) and antinociceptive (11,12) effects. The traditional uses have also been reported in literature (13).

It was reported that different Caper species contained bioactive compounds such as glucosinolates, alkaloids, flavonoids and phenolic acids which are mediated by biological activities (11,14).

There are some studies on hypoglycemic and antioxidant activity of different *C. ovata* var. *Palaestina* extracts generally performed. In this study, it was planned to investigate the inhibiting effect on digestive enzymes correlated to diabetes and antioxidant effects of 70% ethanol extracts of flower and fruits by soxhlet extraction. In this research, the inhibitory activity was carried out by α -amylase and α -glucosidase enzyme inhibitory assays and the antioxidant capacity was performed by radical scavenging activity (DPPH•, ABTS•+ and FRAP methods).

Once the extracts are obtained from the *C. ovata* var. *palaestina*, the next step is to subject the extracts to some *in vitro* bioassay protocols in order to examine whether

the extracts are active or not. *In vitro* assays are usually faster, specific and not much amount of the extracts are used. Furthermore, some of the *in vitro* methods employed include chemical and enzymatic procedures, which depend on spectrophotometric analysis. For instance, in evaluating plants as possible anti-diabetic drugs, several *in vitro* models are used to assess the anti-diabetic effects and mode of actions as well. These models include enzyme inhibition-based assays (e.g. α -amylase, α -glucosidase and glucose 6-phosphatase inhibitions), glucose uptake bioassays (using cell lines such as C2C12 myocytes, 3T3-L1 pre-adipocytes and human Chang liver cells) and stimulation of insulin release (15). In *in vivo* approach, animals are used to investigate the efficacy, mode of action and side effects of the plant extracts. Furthermore, in DM, several models are employed. These include chemically induced animal models such as alloxan and streptozotocin-induced diabetic animals that are mostly used for the induction of T1D (16). In this study fruit extracts were found most active *in vitro* tests and may be recommended for *in vivo* tests.

MATERIALS AND METHODS

Chemicals

Chromatographic grade distilled water, HPLC grade methanol analytical grade formic acid was used for HPLC analyses.

Plant Material and Preparation of Extracts

C. ovata var. *palaestina* flower (500 g) and fruits (500 g) were harvested in August from Akpınar Village in Adıyaman Province, which is located within the borders of Turkey. The plant material was identified with AEF No 26797 herbarium voucher. After drying under suitable conditions, the dried flowers and fruits were pulverized and extracted separately using 70% ethanol (2.5 L) in soxhlet (continuous extraction) apparatus for 8 h. The extracts were evaporated in a rotavapor under reduced pressure at 38 °C and the obtained crude extracts as *C. ovata* var. *palaestina* flower extract (CFW) and fruit extract (CFR) were stored in dark at -20°C.

The Enzyme Inhibition Assay

The α -glucosidase and α -amylase inhibitory assay was established according to the method described by Paşayeva et al., (17). The extracts were tested in 37-1200 μ g/mL concentrations. The 50 μ L of enzyme solution were added on various concentrations of extract solution (50 μ L) and were preincubated at 37°C for 10 min. Then the 50 μ L of 5 mM PNPG was added and the enzymatic reaction was initiated. With the addition of 2 mL of 0.2 mM Na₂CO₃ solution the reaction was stopped. The absorbance was read at 400 nm.

The sample (40 μ L) concentrations were used between 4-2000 μ g/mL. In this assay porcine pancreatic α -amylase solution was prepared in cold distilled water (4 U/mL). In this assay the dilution range of extracts/sub-extracts were between 4-2000 μ g/mL. The enzyme solution, extract or positive control acarbose and sodium phosphate buffer solution were mixed. After preincubation at 25°C the starch solution was added and held on at 25°C for 3 min. Then the color reagent (dinitrosalicylic acid) was added and held on 85°C water bath for 15 min. The absorbance was measured at 540 nm.

The Total Phenolic (TPC) and Total Flavonoid Content (TFC)

The TPC was described by the method of Paşayeva et al., (17). Folin-Ciocalteu reagent was used in this assay, and TPC was calculated as milligram of gallic acid equivalents (GAE) per gram of extract. The TFC was performed by the method Paşayeva et al., (17). As described in this method, absorbance was measured at 510 nm and TFC was determined as milligram of catechin equivalent (CA) per gram of extract. The TPC and TFC tests were performed in triplicate.

In vitro Antioxidant Capacity

The DPPH radical scavenging assay

1,1-diphenyl-2-picrylhydrazyl radical (DPPH[•]) scavenging activity of samples were determined using the method of Gyamfi and Aniya (18). Stock solutions of samples were prepared in methanol at 4 mg/mL concentrations. Then the stock solutions were diluted to obtain working concentrations (0.025, 0.05, 0.1, 0.2, 0.4, 0.6, 0.8, 1 and 2 mg/mL). A volume of 50 µL of a sample concentration was mixed with 950 µL 0.05 M Tris-HCl buffer and 1 mL of DPPH[•] reagent. After the incubation, the absorbance was read at 517 nm. In this study, butylated hydroxyanisole (BHA) was the reference standard and all tests performed in triplicate. The % inhibition was calculated using Equation (3).

$$\% \text{ inhibition} = \left[\frac{\text{Abs}_{\text{control}} - \text{Abs}_{\text{sample}}}{\text{Abs}_{\text{control}}} \times 100 \right] \quad (3)$$

The ABTS radical scavenging assay

The ABTS^{•+} was performed according to the method of Paşayeva et al., (17). In this assay, the ABTS^{•+} working solution was diluted with methanol. Then fresh 2850 µL of ABTS^{•+} reagent was mixed with sample. Trolox was chosen as a positive control and the antioxidant capacity was determined as Trolox equivalent. The absorbance was read at 734 nm.

The FRAP assay

The ferric reducing ability power (FRAP) test was described to the method by Paşayeva et al., (17). In this assay, absorbance was read at 593 nm. The FRAP values were determined using FeSO₄·7H₂O as a standard ferric reducing activity. The results were expressed as mmol of Fe²⁺ equivalents per g of extract/fraction weight (mmol Fe²⁺ /g).

Statistical Analysis

All statistical analyses were conducted using GraphPad Prism Software Version 8.0 (La Jolla, CA, USA). The results were expressed as the mean ± standard deviation

(SD). Statistically significant values were compared using one-way ANOVA with Multiple Comparison Test and p-values of less than 0.05 were considered statistically significant.

RESULTS

The Enzyme Inhibitory Activity

The results of α-glucosidase and α-amylase inhibitory activities of extracts were given in Figure I. In this study α-glucosidase inhibitory activity of CFR extract was found higher (P < 0.000664) than the activity of CFW (IC₅₀ = 271.72 ± 0.41 µg/mL). The results of α-amylase inhibitory effect showed that among the extracts CFR possessed the highest inhibition effect (IC₅₀ = 142.07 ± 0.85 µg/mL) than acarbose as a positive control (Table I). According to results CFW extract showed %42 α-glucosidase and %32 α-amylase inhibitory activities at 1200 and 2000 mg/mL, respectively. The IC₅₀ values for CFW did not calculated in these concentrations.

The Total Phenolic Content (TPC) and Total Flavonoid Content (TFC)

The results of extracts were listed in Table I. In this study, the highest TPC and TFC was found in CFR extract (26.40 ± 0.02 mgGAE/g_{extract} and 8.33 ± 0.30 mgCA/g_{extract}) (P < 0.001).

Antioxidant Activity

The DPPH Radical Scavenging Capacity

The results for DPPH[•] antioxidant capacity of extracts are presented in (Figure II). According to results CFR extract showed 32% antioxidant capacity and CFW extract 23% DPPH radical scavenging capacity at 2000 mg/mL. None of the extracts showed high capacity than BHA as positive standard.

The ABTS Radical Scavenging Activity

The concentrations of samples and BHA were 0.5 mg/mL to determine ABTS radical scavenging activity. According to the results, the CFW extract showed the highest activity (0.18 ± 0.01 Trolox/g_{extract}) (P < 0.000360) (Table I).

The FRAP Results

The results were showed that, CFW extract was more active (262.69 ± 2.27 mmol Fe²⁺/g_{extract}) (P < 0.000590) than CFR extract (198.15 ± 1.236 mmol Fe²⁺/g_{extract}). Trolox was used as a standard.

DISCUSSION

Table I. Total phenolic, total flavonoid content, antioxidant and enzyme inhibitory activity results of *C. ovata* var. *palaestina* extracts.

Samples	α-glucosidase assay IC ₅₀ (µg/mL)	α-amylase assay IC ₅₀ (µg/mL)	TPC (mg GAE /g _{extract})	TFC (mg CA /g _{extract})	FRAP (mmol Fe ²⁺ /g _{extract} /mmol Fe ²⁺)	ABTS (µM Trolox/g _{extract} /µM Trolox/)
CFR	142.07 ± 0.85 ^{b,a}	271.72 ± 0.41 ^{c,a}	26.40 ± 0.02 ^{a,d}	8.33 ± 0.30 ^c	198.15 ± 1.24 ^{c,d}	0.17 ± 0.01 ^{c,a}
CFW	-	-	17.24 ± 0.02 ^{d,e}	7.73 ± 0.15 ^d	262.69 ± 2.27 ^{d,e}	0.18 ± 0.01 ^{a,e}
Trolox	-	-	-	-	6235.01 ± 1.63 ^{a,b}	-
BHA	-	-	-	-	-	0.73 ± 0.01 ^{b,a}
Acarbose	231.27 ± 0.24 ^a	221.79 ± 0.23 ^a	-	-	-	-

Values are expressed as mean ± SD (n = 3). CFR ethanol extract of *C. ovata* var. *palaestina* fruit, CFW ethanol extract of *C. ovata* var. *palaestina* flower. Values followed by the same letter are not significantly different (P < 0.05).




Figure I. α-glucosidase (a) and α-amylase (b) inhibitory activities of *C. ovata* var. *palaestina* extracts.




Figure II. DPPH radical scavenging capacities of *C. ovata* var. *palaestina* extracts.

It is known that more than 387 million people suffer from DM around the world. Type 2 diabetes is a type of DM and described by hyperglycemia. It is well known that type 2 diabetes is caused by reactive oxygen species (ROS) (19).

There are a numerous stuiies on α-glucosidase, α-amylase inhibitory effects and antioxidant properties of *C. ovata* var. *palaestina*. The objective of this research is to evaluate the hypoglycemic activity by α-glucosidase, α-amylase methods and antioxidant activities of ethanol extracts of this plant prepared by soxhlet method.

In a study, the ethanol and aqueous extracts of *C. ovata* var. *palaestina* buds and fruits were administered intraperitoneally to alloxan-induced diabetic BALB-c mice with 100, 300, 500mg/kg doses. As a result, significant hypoglycemic activity was found in fruit-aqueous extract the dose of 100mg/kg, 300mg/kg and bud-aqueous extract at 500mg/kg doses. In the same study, the highest TPC and TFC was found in fruit-ethanol extract (963.3±84.85 mg GAE/100g Extract for TPC and 2785±21.21mgQE/100g Extract for TFC) and the highest antioxidant activity was determined in bud-aqueous extract (IC₅₀=0.4390±0.0105 mg/mL for DPPH and IC₅₀=0.2139±0.006 mg/mL for ABTS) (5). In another study, the hypoglycemic effect of *C. ovata* var. *palaestina* extracts was evaluated in alloxan-induced diabetic mice. For this purpose, diabetic mice were administered with 100, 300, 500 mg/kg (i.p.) doses of methanol extract of bud and fruit. The results revealed that fruit-methanol 500 mg/kg, bud-methanol 300 mg/kg, bud-methanol 500 mg/kg extracts showed significant hypoglycemic activities. Furthermore, in this study the bud-methanol extract was demonstrated the most potent antioxidant activity (IC₅₀= 0.096±0.007 mg/mL for

DPPH and IC₅₀=0.063±0.009 mg/mL for ABTS). Although, the highest TPC and TFC was found in fruit-methanol extract (1017.42±44.18 mg GAE/100g Extract for TPC and 2990±21.21 mgQE/100g Extract for TFC) (6). Additionally, the anti-inflammatory effect, antimicrobial and antibacterial activity and wound healing properties of different extracts of *C. ovata* var. *palaestina* were investigated (8,9,5).

In this study, the hypoglycemic and antioxidant activity of ethanol extract of *C. ovata* var. *palaestina* flower and fruits were investigated. The fruit extract was found the most active in term of α-amylase and α-glucosidase inhibition effect. By the same, the higher TPC and TFC and the DPPH radical scavenging activities were found in this extract. On the other hand, the highest FRAP values and ABTS activity were found in the flower extract. Some investigations showed that the high potent α-amylase and α-glucosidase inhibition and antioxidant activity were related to the high phenolic/flavonoid content of extracts. Therefore, we can consider that the potent α-amylase and α-glucosidase inhibition and antioxidant activity of CFR extract may be explained by the presence of these compounds. According to the earlier studies *C. ovata* var. *palaestina* contained alkaloids, lipids, polyphenols, flavonoids, and glucosinolates (5). Considering the earlier studies on anti-diabetic and antioxidant activities of the plant, it can be said that the phenolic compounds and flavonoids are responsible for these activities (5,6,8,9).

CONCLUSION

In this study fruit extract was found the most active in terms of α-amylase and α-glucosidase inhibitory effect and the antioxidant activity. As a result, this extract can be considered a natural source for antioxidants and antidiabetic agents after the detailed investigation. Furthermore, the investigations are beneficial for the development of novel products in the pharmaceutical and food industries.

Acknowledgments

The authors are thankful to Kübra Olgan for providing plant material.

REFERENCES

1. Maritim AC, Sanders RA, Watkins JB 3rd. Diabetes, oxidative stress, and antioxidants: A review. *J Biochem Mol Toxicol* 2003; 17 (1):24-38.
2. Surampudi PN, John-Kalarickal J, Fonseca VA. Emerging concepts in the pathophysiology of type

- 2 diabetes mellitus. Mt Sinai J Med 2009; 76 (3):216-226.
3. Hung HY, Qian K, Morris-Natschke SL, et al. Recent discovery of plant-derived anti-diabetic natural products. Nat Prod Rep 2012; 29(5):580-606.
 4. Sloop KW, Michael MD, Moyers JS. Glucagon as a target for the treatment of type 2 diabetes. Expert Opin Ther Targets 2005; 9(3):593-600.
 5. Okur ME, Polat DC, Ozbek H, et al. Evaluation of the antidiabetic property of *Capparis ovata* Desf. var. *palaestina* Zoh. Extracts using in vivo and in vitro approaches. Endocr Metab Immune Disord Drug Targets 2018; 18(5):489-501.
 6. Okur ME, Özbek H, Polat DÇ, et al. Hypoglycemic activity of *Capparis ovata* Desf. var. *Palaestina* Zoh. methanol extract. Brazilian Journal of Pharmaceutical Sciences 2018; 54(3):1-9.
 7. Aghel N, Rashidi I, Mombeini A. Hepatoprotective activity of *Capparis spinosa* root bark against CCl4 induced hepatic damage in mice. Iran J Pharm Res 2007; 6(4):285-290.
 8. Muhaidat R, Al-Qudah MA, Al-Shayeb A, et al. Chemical profile and antibacterial activity of crude fractions and essential oils of *Capparis ovata* Desf. and *Capparis spinosa* L. (Capparaceae). Int J Integr Biol 2013; 14(1):39.
 9. Okur ME, Ayla Ş, Çiçek Polat D, et al. Novel insight into wound healing properties of methanol extract of *Capparis ovata* Desf. var. *palaestina* Zohary fruits. Journal of Pharmacy and Pharmacology 2018; 70(10):1401-1413.
 10. Ergur BU, Gazioglu I, Sen A, et al. *Capparis ovata* treatment suppresses inflammatory cytokine expression and ameliorates experimental allergic encephalomyelitis model of multiple sclerosis in C57BL/6 mice. J Neuroimmunol 2016; 298:106-116.
 11. Arslan R, Bektas N. Antinociceptive effect of methanol extract of *Capparis ovata* in mice. Pharm Biol 2010; 48(10):1185-1190.
 12. Arslan R, Bektas N, Ozturk Y. Antinociceptive activity of methanol extract of fruits of *Capparis ovata* in mice. J Ethnopharmacol 2010; 131(1):28-32.
 13. Tlili N, Elfalleh W, Saadaoui E, et al. The caper (*Capparis* L.): Ethnopharmacology, phytochemical and pharmacological properties. Fitoterapia 2011; 82(2):93-101.
 14. Gull T, Anwar F, Sultana B, et al. *Capparis* species: A potential source of bioactives and high-value components: A review. Industrial Crops and Products 2015; 67:81-96.
 15. Beretta G, Facino RM. Recent advances in the assessment of the antioxidant capacity of pharmaceutical drugs: from *in vitro* to *in vivo* evidence. Analytical and Bioanalytical Chemistry 2010; 398(1):67-75
 16. Wang Y, Simar D, Fiatarone Singh MA. Adaptations to exercise training within skeletal muscle in adults with type 2 diabetes or impaired glucose tolerance: A systematic review. Diabetes/Metabolism Research and Reviews 2009; 25(1):13-40.
 17. Paşayeva L, Özalp B, Fatullayev H. Potential enzyme inhibitory properties of extracts and fractions from fruit latex of *Ficus carica*-based on inhibition of α -amylase and α -glucosidase. Journal of Food Measurement and Characterization 2020; 14 (5):2819-2827.
 18. Gyamfi MA, Aniya Y. Antioxidant properties of Thonningianin A, isolated from the African medicinal herb, *Thonningia sanguinea*. Biochem Pharmacol 2002; 63(9):1725-1737.
 19. Devasahayam G, Burke DJ, Sturgill TW. Golgi manganese transport is required for rapamycin signaling in *Saccharomyces cerevisiae*. Genetics 2007; 177(1):231-238.